Inspira Technologies' remarkable 96% accuracy in HYLA blood sensor clinical trials positions the company to target both the $5.7 billion blood gas analyzer market and the $19 billion mechanical ventilation market; Strengthened by FDA-cleared ART100 already being deployed in U.S. hospitals and HYLA FDA submission on track for H2 2025; Company shifts focus to now accelerate development of flagship INSPIRA ART500 system, potentially transforming respiratory care for millions of ICU patients worldwide

PESG Research releases an update following Inspira Technologies' (NASDAQ: IINN)* recent strategic developments and clinical achievements: Inspira has emerged as a potential disruptive force in respiratory care with its integrated technology approach. The company's recent clinical studies demonstrating 96% accuracy for its AI-powered HYLA blood sensor represent a significant technological validation as it targets multiple high-value healthcare segments.

Inspira's integrated technology ecosystem combines the HYLA blood sensor with its revolutionary respiratory support platform. The HYLA system demonstrated impressive clinical results at Sheba Hospital (ranked among the world's top 8 hospitals by Newsweek), with 96% accuracy in a key parameter and 92.3% accuracy in detecting oxygen deficiencies. This non-invasive monitoring technology aims to replace traditional blood draws, targeting the blood gas analyzer market projected to reach $5.7 billion by 2030, with FDA submission planned for H2 2025.

Building on the success of its FDA-cleared INSPIRA ART100 system, Inspira's latest update has noted that it is accelerating development of its flagship INSPIRA ART500 system. CEO Dagi Ben-Noon recently emphasized this strategic focus: "Once fully integrated, our INSPIRA ART500 is intended to be equipped with the HYLA blood sensor." This integrated approach targets the $19 billion mechanical ventilation market by offering a less invasive alternative that allows patients to remain awake during treatment.

The company's technology addresses a critical healthcare challenge: the limitations of traditional mechanical ventilation. With approximately 20 million patients requiring mechanical ventilation annually and mortality rates exceeding 50% under current protocols, Inspira's approach—enabling conscious patient treatment with continuous monitoring—represents a potential paradigm shift in critical care management. By targeting the estimated 100,000 ventilators in the U.S. with a safer alternative, Inspira aims to significantly improve patient outcomes while creating substantial market value.

Looking ahead, the company has noted that expects to receive a prepayment from its U.S. distributor for INSPIRA ART100 systems in the coming weeks. With a clear roadmap focusing on accelerating the INSPIRA ART500 system, expanding U.S. market presence, and advancing the HYLA FDA submission, Inspira is positioned at the forefront of respiratory care innovation when demand for alternatives to traditional mechanical ventilation has never been higher.

News Highlights from Inspira:

• Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care
• Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates
• Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy

>> Click here to Subscribe for more updates like this or go to https://www.pesgresearch.com/subscribe

* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published PESG Research, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250318521060/en/